Clinical Trial Update: DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME [Phase 3]

View source ↗

Summary

A DRCR.Net Phase 3 trial comparing aflibercept monotherapy to bevacizumab with deferred aflibercept for central-involved diabetic macular edema completed, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Avastin (bevacizumab)
• EYLEA (Aflibercept)

Snippet

Sponsor: Jaeb Center for Health Research | Conditions: Diabetic Macular Edema | Phase 3 | Status: COMPLETED | Results posted: 2024-04-25